Technical Analysis for BMEA - Biomea Fusion, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Upper Bollinger Band Walk | Strength | 3.15% | |
50 DMA Resistance | Bearish | -1.21% | |
Stochastic Reached Overbought | Strength | -1.21% | |
Upper Bollinger Band Walk | Strength | -1.21% | |
Weak + Overbought | Other | -1.21% | |
Overbought Stochastic | Strength | -1.21% | |
Upper Bollinger Band Touch | Strength | -1.21% | |
50 DMA Resistance | Bearish | -4.65% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.65% | |
Pocket Pivot | Bullish Swing Setup | -4.65% |
Alert | Time |
---|---|
Up 3% | about 2 hours ago |
Up 2% | about 2 hours ago |
Up 1% | about 2 hours ago |
Fell Below Previous Day's Low | about 2 hours ago |
Down 1% | about 2 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
T
TraderMike about 1 year ago
I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji). These little biotechs are always interesting after having a big pop based on some good/promising news. The standard plan seems to be to immediately issue a secondary offering -- which BMEA did. So now I'm looking for it to climb back above that offering price of $30 and retest the March high.
View full discussion...
Indicator | Value |
---|---|
52 Week High | 43.64 |
52 Week Low | 8.125 |
Average Volume | 990,403 |
200-Day Moving Average | 14.30 |
50-Day Moving Average | 13.18 |
20-Day Moving Average | 11.53 |
10-Day Moving Average | 11.95 |
Average True Range | 0.93 |
RSI (14) | 50.25 |
ADX | 18.08 |
+DI | 24.48 |
-DI | 21.40 |
Chandelier Exit (Long, 3 ATRs) | 10.65 |
Chandelier Exit (Short, 3 ATRs) | 13.00 |
Upper Bollinger Bands | 13.12 |
Lower Bollinger Band | 9.95 |
Percent B (%b) | 0.72 |
BandWidth | 27.50 |
MACD Line | -0.14 |
MACD Signal Line | -0.42 |
MACD Histogram | 0.2794 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.26 | ||||
Resistance 3 (R3) | 13.35 | 13.10 | 13.09 | ||
Resistance 2 (R2) | 13.10 | 12.84 | 13.06 | 13.03 | |
Resistance 1 (R1) | 12.67 | 12.68 | 12.55 | 12.58 | 12.98 |
Pivot Point | 12.42 | 12.42 | 12.36 | 12.38 | 12.42 |
Support 1 (S1) | 11.99 | 12.16 | 11.87 | 11.90 | 11.50 |
Support 2 (S2) | 11.74 | 12.00 | 11.70 | 11.45 | |
Support 3 (S3) | 11.31 | 11.74 | 11.39 | ||
Support 4 (S4) | 11.22 |